

SUPPLEMENTAL MATERIAL

TABLE S1 Bedaquiline AST results

Strain	Bedaquiline [mg/L]										MIC [mg/L]	Day when growth control was > 400 growth units	MIRU-VNTR																							
	0.0125	0.025	0.05	0.1	0.2	0.4	0.8	1.6	3.2	6.4			154	424	577	580	802	960	1644	1955	2059	2163b	2165	2347	2401	2461	2531	2687	2996	3007	3171	3192	3690	4052	4156	4348
Reference strain																																				
H37Rv	R	R	R	R	R	S	S	S	S	S	0.4	9.5	2	2	4	3s	1	3	2	2	2	5	3	4	2	3	6	1	3	3	3	3	5	5	2	2
Treatment-naïve clinical isolates																																				
2014 179741	R	R	R	R	R	S	S	S	S	S	0.4	8.5	2	3	2	2	3	6	4	4	2	2	4	4	2	2	5	1	5	2	3	5	3	7	4	3
2014 180020	R	R	R	R	S	S	S	S	S	S	0.2	7	2	4	4	2	3	2	3	5	2	4	4	4	4	2	5	1	7	3	3	5	3	8	2	4
2014 500093	R	R	R	R	R	S	S	S	S	S	0.4	7.5	2	2	3	2	3	3	3	3	2	3	3	4	4	2	5	1	5	3	3	2	3	7	1	2
2014 180530	R	R	R	R	R	R	S	S	S	S	0.8	10.5	2	2	3	2	4	4	3	4	2	5	3	4	4	2	5	1	4	3	2	3	3	8	1	2
2014 180401	R	R	R	R	R	S	S	S	S	S	0.4	8	2	4	4	2	3	3	3	5	2	5	4	4	4	2	5	1	7	3	3	5	3	8	2	3
2013 178018	R	R	R	R	R	R	S	S	S	S	0.8	9.5	2	2	3	2	3	5	3	3	1	5	2	4	4	2	5	1	5	3	3	4	3	6	3	2
2013 500156	R	R	R	R	R	S	S	S	S	S	0.4	8.5	2	2	4	2	2	3	4	2	2	3	2	4	2	2	5	1	5	3	3	3	3	5	2	2
2013 177527	R	R	R	R	R	S	S	S	S	S	0.4	8	2	2	5	2	3	3	3	3	2	2	3	4	2	2	5	1	5	2	3	3	4	6	2	2
2013 177741	R	R	R	R	R	R	S	S	S	S	0.8	10	2	2	3	2	3	3	3	2	2	3	3	4	2	2	6	1	5	3	3	3	3	5	2	2
2013 177633	R	R	R	R	R	R	S	S	S	S	0.8	8.5	2	2	3	2	2	5	3	3	2	6	3	4	4	2	5	1	5	3	3	3	3	4	3	2
Multidrug-resistant (MDR) clinical isolates (no pretreatment with bedaquiline)																																				
2014 186010	nd	nd	nd	R	R	S	S	S	S	S	0.4	8	2	1	4	2	2	3	4	2	2	4	2	4	2	2	5	1	5	3	3	4	3	5	2	2
2014 186005	nd	nd	nd	R	R	R	S	S	S	S	0.8	12	2	4	5	2	3	3	3	5	2	6	2	4	4	2	5	1	5	3	3	5	3	8	2	3
2013 186106	nd	nd	nd	R	R	S	S	S	S	S	0.4	13	2	4	4	2	2	5	1	3	2	1	3	4	4	2	5	1	1	3	3	4	3	7	3	2
2013 186119	R	R	R	R	R	R	S	S	S	S	0.8	12	2	4	4	2	3	3	3	3	1	5	4	4	4	1	5	1	7	3	3	5	3	7	4	3
2012 186116	R	R	R	R	R	S	S	S	S	S	0.4	10	2	2	3	2	2	5	3	3	2	3	3	3	4	2	3	1	5	3	3	3	3	5	2	2
2011 186014	R	R	R	R	R	R	S	S	S	S	0.8	14	1	3	2	2	5	4	3	3	2	2	2	4	1	2	5	1	5	3	3	2	2	6	2	2
2011 186010	R	R	R	R	R	R	S	S	S	S	1.6	23	2	4	4	2	3	3	2	8	1	5	4	4	4	2	6	1	5	3	3	5	3	10	5	3
2011 186003	R	R	R	R	R	S	S	S	S	S	0.4	9	2	4	4	2	3	3	3	5	2	6	3	4	1	2	5	1	5	3	3	2	2	6	2	2
2012 186105	R	R	R	R	R	R	S	S	S	S	0.8	8	2	5	4	2	1	4	2	3	2	4	2	4	1	1	6	1	5	3	5	3	3	8	2	2
2013 186121	R	R	R	R	R	R	R	S	S	S	1.6	14	2	2	3	2	0	3	3	2	2	5	2	4	2	2	5	1	4	3	3	3	3	2	2	2
2013 186114	R	R	R	R	R	S	S	S	S	S	0.4	10.5	2	4	4	2	3	3	3	7	2	6	4	4	4	2	5	1	5	3	3	5	3	8	2	3
Extremely-drug resistant (XDR) clinical isolates																																				
2011 186000 [†]	nd	nd	nd	R	R	R	S	S	S	S	0.8	18	2	4	4	2	3	3	2	8	1	5	4	4	4	2	6	1	5	3	3	5	3	10	5	3
2013 186116 ^{**}	nd	nd	nd	R	R	R	R	R	R	S	6.4	10	2	4	4	2	3	3	2	8	1	5	4	4	4	2	6	1	5	3	3	5	3	10	5	3
2014 186023 ^{**}	nd	nd	nd	R	R	R	R	R	R	S	6.4	23	2	4	4	2	3	3	2	8	1	5	4	4	4	2	6	1	5	3	3	5	3	10	5	3

nd: not determined

[†] bedaquiline pretreatment-naïve

^{**} bedaquiline posttreatment isolate with acquired bedaquiline resistance

TABLE S2 Delamanid AST results

Strain	Delamanid [mg/L]									MIC [mg/L]	Day when growth control was > 400 growth units	MIRU-VNTR																							
	0.00125	0.0025	0.005	0.01	0.02	0.04	0.08	0.16	0.32			154	424	577	580	802	960	1644	1955	2059	2163b	2165	2347	2401	2461	2531	2687	2996	3007	3171	3192	3690	4052	4156	4348
Reference strain																																			
H37Rv	R	R	R	S	S	S	S	S	S	0.01	9.5	2	2	4	3s	1	3	2	2	2	5	3	4	2	3	6	1	3	3	3	3	5	5	2	2
Treatment-naïve clinical isolates																																			
2013 178018	R	R	R	R	S	S	S	S	S	0.02	9.5	2	2	3	2	3	5	3	3	1	5	2	4	4	2	5	1	5	3	3	4	3	6	3	2
2013 500156	R	R	R	R	R	S	S	S	S	0.04	8.5	2	2	4	2	2	3	4	2	2	3	2	4	2	2	5	1	5	3	3	3	5	2	2	
2013 177527	R	R	R	S	S	S	S	S	S	0.01	8	2	2	5	2	3	3	3	2	2	3	4	2	2	5	1	5	2	3	3	4	6	2	2	
2013 177741	R	R	R	S	S	S	S	S	S	0.01	10	2	2	3	2	3	3	3	2	2	3	3	4	2	2	6	1	5	3	3	3	5	2	2	
2013 177633	R	R	R	S	S	S	S	S	S	0.01	8.5	2	2	3	2	2	5	3	3	2	6	3	4	4	2	5	1	5	3	3	3	4	3	2	
2013 500126	R	R	S	S	S	S	S	S	S	0.005	7	2	2	4	2	4	3	2	2	2	4	2	4	2	2	5	1	5	3	2	3	3	5	2	2
2013 500136	R	R	R	S	S	S	S	S	S	0.01	7.5	2	2	3	2	3	8	3	6	2	2	3	4	4	2	5	1	6	3	3	4	7	6	3	2
2013 176428	R	R	R	S	S	S	S	S	S	0.01	7.5	2	4	4	2	3	4	3	3	2	2	2	4	2	2	6	1	5	3	3	3	4	4	2	2
2013 176598	R	R	R	R	S	S	S	S	S	0.02	8	2	3	4	2	4	3	1	2	2	4	3	4	2	2	5	1	4	3	3	3	4	5	2	2
2013 176794	R	R	R	R	S	S	S	S	S	0.02	8	2	2	4	2	5	3	3	2	2	4	2	4	2	2	5	1	4	3	3	4	3	5	2	2
Multidrug-resistant (MDR) clinical isolates (no pretreatment with delamanid)																																			
2013 186119	R	R	R	R	R	S	S	S	S	0.04	12	2	4	4	2	3	3	3	3	1	5	4	4	4	1	5	1	7	3	3	5	3	7	4	3
2012 186116	R	R	R	S	S	S	S	S	S	0.01	10	2	2	3	2	2	5	3	3	2	3	3	3	4	2	3	1	5	3	3	3	5	2	2	
2011 186014	R	R	R	S	S	S	S	S	S	0.01	14	1	3	2	2	5	4	3	3	2	2	2	4	1	2	5	1	5	3	3	2	2	6	2	2
2011 186010	R	R	R	S	S	S	S	S	S	0.01	23	2	4	4	2	3	3	2	8	1	5	4	4	4	2	6	1	5	3	3	5	3	10	5	3
2011 186003	R	R	R	S	S	S	S	S	S	0.01	9	2	4	4	2	3	3	3	5	2	6	3	4	1	2	5	1	5	3	3	2	2	6	2	2
2012 186105	R	R	S	S	S	S	S	S	S	0.005	8	2	5	4	2	1	4	2	3	2	4	2	4	1	1	6	1	5	3	5	3	3	8	2	2
2013 186121	R	R	R	S	S	S	S	S	S	0.01	14	2	2	3	2	0	3	3	2	2	5	2	4	2	2	5	1	4	3	3	3	3	2	2	2
2013 186114	R	R	R	S	S	S	S	S	S	0.01	10.5	2	4	4	2	3	3	3	7	2	6	4	4	4	2	5	1	5	3	3	5	3	8	2	3
2013 186101	R	R	R	S	S	S	S	S	S	0.01	10	2	4	4	2	3	3	3	5	2	6	4	4	4	2	5	1	5	3	3	5	3	1	2	3
2013 186103	R	R	R	S	S	S	S	S	S	0.01	8.5	2	4	4	2	4	3	3	4	1	4	4	4	4	2	5	1	7	3	3	6	3	7	4	3
Extremely drug-resistant (XDR) clinical isolates																																			
2014 186009*	R	R	R	S	S	S	S	S	S	0.01	30	2	4	4	2	3	3	2	8	1	5	4	4	4	2	6	1	5	3	3	5	3	10	5	3
2014 186011*	R	R	R	S	S	S	S	S	S	0.01	31	2	4	4	2	3	3	2	8	1	5	4	4	4	2	6	1	5	3	3	5	3	10	5	3
2014 180114**	R	R	R	R	R	R	R	R	R	>0.32	25	2	4	4	2	3	3	2	8	1	5	4	4	4	2	6	1	5	3	3	5	3	10	5	3
2014 186023**	R	R	R	R	R	R	R	R	R	>0.32	38	2	4	4	2	3	3	2	8	1	5	4	4	4	2	6	1	5	3	3	5	3	10	5	3
2014 181148**	R	R	R	R	R	R	R	R	R	>0.32	20.5	2	4	4	2	3	3	2	8	1	5	4	4	4	2	6	1	5	3	3	5	3	10	5	3

* delamanid pretreatment-naïve

** delamanid posttreatment isolate with acquired delamanid resistance




FIGURE S1 Graphical representation of the relatedness of the strains according to MIRU-VNTR results. The figure contains all strains of the study. The study's XDR strains and one MDR strain share the same MIRU-VNTR pattern (represented by *). The dendrogram was calculated using the MIRU-VNTRplus web application (<http://www.miru-vntrplus.org/MIRU/index.faces>) and neighbour-joining method (1).

Supplementary Literature

1. Saitou N, Nei M. 1987. The neighbor-joining method: a new method for reconstructing phylogenetic trees. *Molecular Biology and Evolution*4:406-425.